Feb 7th 2023 - Mar 21st 2023
Monday morning pre-market screamer 😱 candidates: ... See more
SIMILAR SETUP TO $AMAM, $HTGM, $APVO, $APCX Vo... See more
Feb 7th 2023 - Mar 21st 2023
$SAVA “Treatment also eased depression and dementi... See more
Simufilam reduced dementia-related behavior at 9 m... See more
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 7th 2023 - Mar 21st 2023
They voluntarily suspended phase 3 bc they are see... See more
$PALI phase 2 coming WOOOOO!! !
Monday morning pre-market screamer 😱 candidates: 🚨🚨🚨💎💎💎🔥🔥🔥 $TCBP Phase 2 update still pending-huge potential on this nano float $BOXD over $1 easy $ALLR PT $.50 $HTGM she’s ready for another big run This week was very good to me.
SIMILAR SETUP TO $AMAM, $HTGM, $APVO, $APCX Volume increasing since last week ✅ Low float recent IPO ✅ Strong future trial pipeline ✅ Time for the next leg up towards IPO price!
SHOULD be some awesome opportunities this week, study study study!
$ATNM positive news in their acute myeloid leukemia trials 👇🏼 53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches It's time to get in before we blast off to $12+ next!
$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”
Simufilam reduced dementia-related behavior at 9 months on the Neuropsychiatric Inventory (NPI), a clinical tool widely used to measure changes in dementia-related behavior.
The open label study is a true gift which gives us insight on both health and benefit issues and the med looks great on both counts.
$SAVA September 3rd 2021 Remi Barbier said, "I truly believe Cassava Sciences is one clinical program away from greatness.
$SAVA Per press release dec 6 2022, Remi stated administration of drug for OL study completed and he is "THRILLED" with the clinical development, or what he see to this date.
$SAVA , VERA announced positive phase 2b results meeting primary end point.
My prediction: Phase 2 Unbelievable results FDA fast track Phase 3 - go ahead Patients receive sava Market cap 40 B by 2024 Rising to 200 Billion by 2026 Game changer - the only drug in the world to help patients
